PIONEERING THE FUTURE OF MICROBIOME THERAPIES
Crestovo is a clinical-stage biopharmaceutical company developing Full-Spectrum Microbiota™ that harnesses the human gut microbiome. Our lead product candidate, CP101, is currently in a clinical trial called PRISM 3.
LEARN MORE
CRESTOVO
Crestovo is a clinical-stage biopharmaceutical company focused on developing and delivering innovative therapies that harness the human gut microbiome.
Through our industry-leading Full-Spectrum Microbiota™ (FSM™) platform, Crestovo is developing a pipeline of orally-administered therapeutics to treat a range of serious diseases, including recurrent Clostridium difficile infection.
NEWS
6.27.2017
Crestovo Doses Patients in PRISM 3, a Clinical Trial of CP101, a Microbiome Therapy for the Prevention of Recurrent Clostridium difficile Infection
FULL ARTICLE
FULL-SPECTRUM MICROBIOTATM
At Crestovo, we are leveraging our industry-leading Full-Spectrum Microbiota™ (FSM™) platform to develop therapeutics that harness the human gut microbiome to restore diversity of healthy microorganisms. Through this approach, we are working to treat conditions with significant unmet medical need where patients are suffering from dysbiosis, including recurrent Clostridium difficile infection (CDI).
VISIT OUR PLATFORMJOIN OUR TEAM
Crestovo is looking for dynamic, driven individuals to join our team that is focused on treating serious diseases, pioneering breakthroughs in the biopharmaceutical industry and making a positive impact on patients’ lives. Ready to be part of a world-class team at the forefront of the microbiome movement?
CAREER OPPORTUNITIES